ISPOR – The Professional Society for Health Economics and Outcomes Research
The society of health economists and outcomes researchers whose methods and good-practice reports underpin how cancer drugs are valued by HTA bodies and payers.
Founded in 1995, ISPOR has more than 20,000 members in over 100 countries and publishes Value in Health. Its Good Practices Task Force reports set methodological standards for cost-effectiveness modelling, indirect treatment comparisons, real-world evidence, patient-reported outcomes and value frameworks that health technology assessment agencies including NICE, CADTH and IQWiG reference, and its ISPOR and ISPOR Europe conferences are where HTA bodies, industry and academics debate oncology pricing, surrogate endpoints and managed-access schemes. ISPOR also runs the HTA Roundtables, the Value Assessment Frameworks initiative and a large student network, and it partnered with the FDA and payers on the RWE Transparency Initiative.
- Good Practices Task Force reports
- Value in Health
- ISPOR and ISPOR Europe conferences
- HTA Roundtables and RWE Transparency Initiative
Pages like this
not linked directly; found by shared links- CollectionNICE cancer guidance and technology appraisals (UK)
Shares National Institute for Health and Care Excellence, Hazard ratio (HR), Overall survival (OS), Progression-free survival (PFS).
- IdeaPower trials to detect a benefit patients would value, not the smallest detectable one
Shares Hazard ratio (HR), Overall survival (OS), Progression-free survival (PFS), Prices and value.
- IdeaOpen, benchmarked algorithms for lines of therapy and progression from routine data
Shares Weak real-world evidence and registries, Real-world evidence, Progression-free survival (PFS).
- PersonMichael LeBlanc
Shares Hazard ratio (HR), Overall survival (OS), Progression-free survival (PFS).
- IdeaA public rulebook for when an external or synthetic control arm is acceptable
Shares Hazard ratio (HR), Weak real-world evidence and registries, Real-world evidence.
- IdeaEvery patient on an accelerated-approval drug enrolled in a registry until confirmation
Shares Overall survival (OS), Weak real-world evidence and registries, Real-world evidence.
- IdeaA pre-registered standard for emulating trials with real-world data
Shares Hazard ratio (HR), Weak real-world evidence and registries, Real-world evidence.
- IdeaProvisional prices for surrogate-endpoint approvals, reset when survival data arrive
Shares Overall survival (OS), Progression-free survival (PFS), Prices and value.